The “Innovation Cliff to Execution Edge” session at BIO-Europe Spring 2026 spoke against a backdrop of post-COVID capital retrenchment, a disrupted FDA, and the most geopolitically fractured biopharma environment since the pre-ICH era. Moderated by Paul Bridges, President of Consulting at Parexel, the panel featured Carmelida Capaldi, Innovation Manager at Chiesi Farmaceutici; Ricardo Perdigao Henriques, Managing Partner at Biovance Capital — Portugal’s first biotech-dedicated fund; and Arturo Urrios, Venture Partner at Ysios Capital. The session’s central premise was unambiguous: Europe does not have a science problem. It has an execution problem — and closing that gap demands structural changes to capital formation, regulatory architecture, and translational infrastructure.
Diagnosing Europe’s Structural Execution Deficit
The discussion opened with a structural diagnosis of why Europe’s abundant scientific output fails to convert into proportional clinical starts. The Chiesi representative identified fragmentation — regulatory, market access, and business model — as the primary failure mode, not talent scarcity or idea generation. The mechanism is straightforward but corrosive: a single innovative tool attempting to enter multiple EU member states encounters categorically different healthcare entry points, patient engagement pathways, and reimbursement logics in each jurisdiction. As a live illustration, Chiesi’s open innovation team described a concurrent partnership with an Italian startup developing a digital screening tool for chronic respiratory disease patients — a program in which the patient access gateway varies from general practitioners in some states to dedicated digital health platforms in others, reflecting divergent digital health literacy across the bloc. That fragmentation compounds cost, delays proof-of-concept timelines, and erodes the startup’s ability to generate a clean, scalable dataset — precisely the outcome that downstream investors and acquirers require.
The Biovance representative corroborated this framing from an investor lens, noting that while Europe is not short of high-quality ideas, the execution gap relative to the U.S. remains the dominant risk variable. The Ysios representative added a structural observation about the prevailing investment philosophy: European capital has historically gravitated toward assets rather than platforms, a discipline that is now re-asserting itself as the AI-platform hype cycle — which mirrors earlier enthusiasm around technology engines as standalone value drivers — produces familiar patterns of capital overconsumption without proportional clinical validation. The core investment question, as framed by the Ysios partner, reduces to a single diagnostic: is there a therapeutic rationale by which this asset will affect a disease in a way measurable at a clinical endpoint? That question sounds simple, but tracing a credible answer backward from the clinical endpoint through mechanism, biomarker, patient population, and trial design is where most early European companies struggle.
The Parexel moderator added historical context that sharpened the structural argument: Parexel was founded in 1982 explicitly to arbitrage the global regulatory fragmentation that made it nearly impossible to submit a UK dossier in the U.S. The firm evolved into a full-scale CRO precisely because ICH harmonization in the mid-1990s — particularly the E6 Good Clinical Practice guideline — created a common framework that enabled multinational data leverage. The current environment represents a partial reversal of that trajectory. The post-2025 U.S. administration’s reshoring posture, combined with the continued structural deharmonization within Europe, is reintroducing the friction that ICH spent a decade eliminating — and compressing the window during which a European company can build a globally credible dossier before requiring U.S. capital or U.S. regulatory engagement.
De-Risking Frameworks and Capital Structure as Execution Tools
The Chiesi open innovation group operates a seven-person team dedicated to partnering with early-stage external innovation — startups, academic spinouts, and digital health companies — across its three therapeutic focus areas: chronic respiratory disease, care (with concentration in neonatology, prematurity, and cardiology), and rare and ultra-rare diseases. The team’s primary de-risking instrument is what it terms a “fail fast” methodology: collaboratively designing a single, tightly scoped experiment with explicit success criteria, defined KPIs, and binary go/no-go logic that surfaces viability or infeasibility at the earliest technically meaningful decision point. The mechanism matters here — this is not simply early-stage due diligence. It is a structured co-design process in which Chiesi’s scientific and strategic resources are deployed to define the experiment architecture alongside the startup, not merely to evaluate it afterward. The second instrument is active mentorship — covering technical and scientific dimensions, but extending explicitly into strategic and business development competencies that early-stage founders predictably lack. Chiesi operates this model across partnerships in Europe, the U.S. (including collaborations with Mayo Clinic, Northwestern, and MIT), and an emerging presence in China, where the company is building visibility through key opinion leader advisory boards and targeted industry participation.
Biovance Capital — a 60 million-plus fund with five PhDs on the investment team, investing from seed through Series A across all disease areas and modalities — structures de-risking into the deal architecture itself through tranche-based milestone financing. The mechanism creates bidirectional confidence: the company retains a committed capital path contingent on performance, while the investor limits exposure to pre-validated milestones rather than funding an unbroken runway. The fund also deliberately constructs syndicate architecture as a risk management tool — pairing a local or regional biotech-specialized investor with a larger corporate venture or pharma CVC that can deploy significantly larger capital as the asset matures. Governance quality rounds out the framework: independent international board members and experienced scientific advisory boards are treated as structural risk mitigants, not optional prestige additions. The fund’s deal flow demonstrates these principles operationally — a September close on Mondego Bio, a Portuguese cancer immunotherapy company, in a round led by OrbiMed and Torrey Pines Therapeutics, and a same-day announcement at the conference of a first international deal in Ligo Bio, a Dutch company, co-invested alongside Kurma Partners and Angelini Ventures.
The Ysios framework, which typically targets Series A and Series B rounds with a mandate to advance assets toward clinical proof-of-concept, frames de-risking as a calibration problem between underfunding and overexposure. The fund’s newly launched company creation vertical reflects a specific market gap diagnosis: Spain, in particular, has a rich substrate of preclinical innovation and clinical research infrastructure, but lacks the translational connective tissue — experienced drug developers, structured storytelling frameworks, and milestone-mapped capital deployment — that converts scientific potential into investable clinical assets. The venture partner described the fund’s early-stage engagement model as a co-authoring process: defining the narrative arc, sequencing the “reasons to believe” data packages, and accompanying the company through execution rather than simply financing it from a distance. The fund treats this as a time-limited marriage with a defined exit horizon — a framing that makes the upfront alignment on milestones, team composition, and geographic strategy a prerequisite, not a downstream negotiation.
Geographic Sequencing as a Strategic Variable
Within this environment of shifting U.S. regulatory predictability and persistent European fragmentation, the panel converged on a nuanced geographic sequencing framework that rejects both reflexive U.S.-first and parochial Europe-first defaults. The Biovance representative offered the most data-grounded formulation: running a biotech company in Europe costs on average 50% less than in the U.S., with further cost advantages in Southern Europe — a material input to capital efficiency calculations at the preclinical and early clinical stages. However, a U.S.-first posture becomes structurally necessary under several specific conditions: when greater than 80% of target market revenues are U.S.-concentrated (as is the case for certain indications given that the U.S. generates approximately 45% of global pharma revenues while consuming only 10% of global dosage forms); when a large Series B, crossover round, or IPO pathway requires U.S. investor access; or when a U.S. pharma partnership requires U.S. clinical data as a prerequisite. Under those conditions, early FDA engagement — particularly at the pre-IND stage — and access to U.S. key opinion leaders cannot be deferred.
The Ysios partner framed the decision as a complexity-absorption question: can the company, at its current stage and team capacity, absorb the operational, cultural, and financial complexity of a U.S. presence without compromising execution on its core scientific program? If not, the value-maximizing move is to extend European validation until the company can absorb that complexity without diluting focus. The Chiesi representative offered the most geographically ambitious formulation — a three-parallel-geography strategy covering Europe, the U.S., and China simultaneously, with differentiated innovation strategies calibrated to each market’s regulatory maturity, cultural norms, and innovation ecosystem characteristics. For the U.S., that means active university partnerships and open innovation challenges. For China, it means building visibility and KOL relationships from near-zero baseline. For Europe, it means leveraging EIT Health network membership, EIC Corporate Partnership participation, and a dense university partnership network spanning most EU member states.
Spain emerged as a case study in organic ecosystem construction that other European markets are actively studying. The MHRA’s new leadership, as noted by the Parexel moderator, has cited Spain’s trajectory — particularly its rapid rise in clinical trial starts and inward investment attraction, partly enabled by early adoption of EUCTR — as a model for replication. The Ysios partner attributed Spain’s momentum to a combination of cultural energy, the structural advantage of late entry (enabling adoption of established best practices without legacy infrastructure inertia), strong clinical research substrate, and local pharma anchors. The missing layer, as he diagnosed it, is translational infrastructure: experienced drug developers who can take Spain’s research output and convert it into globally competitive development programs, and who are motivated to build that capacity domestically rather than exit to more established ecosystems.
Structural Reforms and the Two-to-Three Year Horizon
Looking ahead, the panel converged on capital structure reform as the single highest-leverage intervention available to European policymakers — and the one most likely to produce compounding returns across the ecosystem. The Biovance representative identified pension fund allocation caps as the binding constraint: European pension funds are currently restricted to allocating a small percentage of assets into venture capital, a regulatory floor that structurally limits the pool of patient, long-duration capital available for Series A and B rounds. The direct consequence is that European companies mature to the point of institutional investability and then exit to U.S. capital markets and acquirers, transferring the majority of value creation outside the continent. Raising those allocation limits would expand the domestic funding base without requiring new government expenditure.
The Ysios partner added a more granular capital architecture concern: the current landscape of regional public funding vehicles operates with insufficient coordination, creating overlapping mandates that can drive valuation inflation rather than genuine risk reduction. The structural fix is not simply more capital — it is capital deployed with incentives specifically calibrated to reduce investor risk at the early stages, thereby expanding the effective risk appetite of the ecosystem without triggering the valuation distortions that characterized the 2020–2021 COVID-era peak. The Chiesi representative aligned on harmonization and capital access as the twin priorities — and added scale as an explicit goal, reflecting the practical reality that European startups frequently succeed in navigating European regulatory complexity only to discover that U.S. regulatory pathways, particularly for digital health tools, are structurally less demanding.
The Parexel moderator pointed to EUCTR implementation as the most immediate regulatory lever: the new clinical trial regulation was designed to harmonize trial activation and data submission across member states, and its core logic — if fully and consistently implemented — would materially compress the timeline from first-in-human to proof-of-concept for European-origin assets. The gap between regulatory intent and operational reality remains the critical variable. Pre-IND interactions with the FDA, already under pressure from the post-2025 administrative disruption and the de-formalization of pre-IND meeting metrics, represent the most acute near-term risk for European companies with U.S. ambitions — and the case for investing in early regulatory strategy and dossier quality before initiating FDA dialogue has never been stronger. Europe’s execution edge, if it is to be realized, will be built on exactly that foundation: structured de-risking, milestone-mapped capital, regulatory fluency on both sides of the Atlantic, and the institutional reforms required to keep the resulting value on the continent long enough to matter.
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
